Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.
暂无分享,去创建一个
A. Wu | S. Forman | M. Jensen | L. Cooper | A. Raubitschek | L. J. Cooper | Michael C. Jensen | Anna M. Wu
[1] S. A. Bush,et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. , 2002, Blood.
[2] B. Wörmann,et al. High‐dose myeloablative radioimmunotherapy of mantle cell non‐hodgkin lymphoma with the iodine‐131–labeled chimeric anti‐CD20 antibody C2B8 and autologous stem cell support. [THIS ARTICLE HAS BEEN RETRACTED] , 2002, Cancer.
[3] M. Rashford,et al. Rituximab: Ongoing and future clinical development. , 2002, Seminars in oncology.
[4] M. Grossbard,et al. Rituximab therapy of B-cell neoplasms. , 2000, Clinical lymphoma.
[5] M. Czuczman,et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Kaminski,et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. , 2000, Blood.
[7] L. Gordon,et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] D. Maloney,et al. Clinical status and optimal use of rituximab for B-cell lymphomas. , 1998, Oncology.
[9] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Wu,et al. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] L. Ginaldi,et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.
[12] E. Warren,et al. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. , 1998, Blood.
[13] J. Ledbetter,et al. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. , 1998, Blood.
[14] J. Renauld,et al. Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. , 1997, Methods.
[15] P. Henkart. Introduction: CTL effector functions , 1997 .
[16] J. Thompson,et al. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. , 1996, Journal of immunology.
[17] P. Robbins,et al. Human tumor antigens recognized by T cells. , 1996, Current opinion in immunology.
[18] K. Cornetta,et al. Human gene marker/therapy clinical protocols. , 1996, Human gene therapy.
[19] T. Tedder,et al. CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.
[20] I. Bernstein,et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.
[21] S. Riddell,et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.
[22] M. Slovak,et al. Human T lymphocyte genetic modification with naked DNA. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] I Royston,et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.
[24] E. Reinherz. Human B lymphocytes , 1986 .